Ixazomib Citrate (MLN9708)

CAS : 1201902-80-8

Ref. 3D-BYB90280

Informations sur le produit

• Nom: Ixazomib Citrate (MLN9708)
• Synonymes: 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid, Ixazomib
• CAS: 1201902-80-8

Description

Ixazomib Citrate (MLN9708) is a proteasome inhibitor that belongs to the class of investigational agents. It has minimal toxicity and is being investigated for use in the treatment of multiple myeloma, a type of cancer that starts in the bone marrow. Ixazomib Citrate inhibits the activity of proteasomes, which are cellular structures responsible for degrading proteins. This inhibition leads to an increase in the number of cells with damaged DNA and an increase in apoptosis. Ixazomib Citrate synergizes with other chemotherapeutic agents, such as bortezomib, to promote apoptosis by activating caspases and decreasing cell proliferation. The biochemical properties of this drug include its ability to inhibit protein synthesis by inhibiting eukaryotic ribosomes and its ability to bind to DNA at specific sites.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 517.12 g/mol
• Formule: C₂₀H₂₃BCl₂N₂O₉
• Degré de pureté: Min. 95%